Measuring health-related quality of life in women on hormone replacement therapy

2003 ◽  
Vol 3 (3) ◽  
pp. 351-361 ◽  
Author(s):  
Harri Sintonen ◽  
Stiina Johansson ◽  
Arto Ohinmaa ◽  
Marjo Apajasalo ◽  
Petri Kainulainen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Has the Impact of Hormone Replacement Therapy on Health-Related Quality of Life Been Undervalued?

2000 ◽  
Vol 9 (2) ◽  
pp. 119-130 ◽  
Author(s):  
Anna N.A. Tosteson ◽  
Sherine E. Gabriel ◽  
Terry S. Kneeland ◽  
Megan M. Moncur ◽  
Paul D. Manganiello ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact

Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument

2005 ◽  
Vol 11 (4) ◽  
pp. 145-151 ◽  
Author(s):  
Stiina Ylikangas ◽  
Harri Sintonen ◽  
Jorma Heikkinen
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
One Year ◽  
The One

Objective: To examine quality of life after a decade of continuous combined hormone replacement therapy. Study design: The 15D, a generic health-related quality-of-life (HRQoL) instrument, was used to evaluate trends in HRQoL in women who used continuous combined hormone replacement therapy (ccHRT; Indivina®, Orion Pharma, Finland) for up to nine years. These women had a mean age of 56 years of age at the start of therapy. Control data on HRQoL were obtained from age-matched women participating in Finnish population health surveys. Results: Relative to controls, ccHRT was associated with significantly better HRQoL after six and nine years of treatment. Dose minimization at 8.5 years was not associated with a decline in HRQoL in the ensuing six months. One year after discontinuation of ccHRT there was evidence of a decline in HRQoL in women who discontinued ccHRT as planned, whereas HRQoL was maintained in women who had continued or resumed ccHRT during the one-year post-study follow-up. The benefits of ccHRT were apparent in multiple dimensions of the 15D, being largest and most robustly reproduced in the dimension 'discomfort and symptoms'. It is conjectured that the effectiveness of ccHRT in relieving symptoms of menopause may have contributed to the improved HRQoL scores registered in other dimensions, in addition to any direct effects of ccHRT on specific aspects of those other dimensions. Conclusions: These data indicate that up to 10 years of low-dose ccHRT has sustained value in the enhancement of HRQoL when used by women for whom relief of symptoms of menopause and control of bleeding are primary objectives of treatment.

scholarly journals Health related quality of life after combined hormone replacement therapy: randomised controlled trial

BMJ ◽  
2008 ◽  
Vol 337 (aug21 2) ◽  
pp. a1190-a1190 ◽  
Author(s):  
A. J Welton ◽  
M. R Vickers ◽  
J. Kim ◽  
D. Ford ◽  
B. A Lawton ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Hormone Replacement ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Randomised Controlled

Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women

2007 ◽  
Vol 13 (3) ◽  
pp. 116-123 ◽  
Author(s):  
Joan Pitkin ◽  
Vera Petrovna Smetnik ◽  
Péter Vadász ◽  
Mika Mustonen ◽  
Kaisa Salminen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Health Related Quality ◽  
Climacteric Symptoms ◽  
Early Postmenopausal Women ◽  
Related Quality ◽  
Health Related

Objective. Hormone replacement therapy (HRT) relieves menopausal symptoms but its effect on health related quality of life (HRQoL) is uncertain. The aim of this study was to assess the effect of three dose regimens of continuous combined HRT, consisting of estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) on HRQoL in early postmenopausal women (last menstrual period 1–3 years before study entry). Study design. This was a 52-week, randomized, double-blind, multinational study comparing E2V (1 mg or 2 mg) plus MPA (2.5 mg or 5 mg) in different dose combinations. The intention-to-treat population comprised 459 women (average age 51.5 years). Main outcome measures. HRQoL was assessed by the Women's Health Questionnaire (WHQ), the 15D Questionnaire and a visual analogue scale (VAS). Results. There were improvements on eight of the nine domains of the WHQ with all dose regimens during the first 12 weeks ( P<0.0001) and an improvement in the remaining domain (menstrual symptoms) with the lower-dose regimens ( P<0.05). These initial improvements in HRQoL were then maintained or augmented over the remainder of the study ( P<0.0001 for change from baseline at 52 weeks for all domains and dose regimens). Mean 15D total score had improved meaningfully and significantly by 12 weeks ( P<0.0001 versus baseline) in all treatment groups and this improvement was maintained thereafter. This improvement in 15D total score was most marked among previous non-users of HRT ( P<0.05 versus previous users). VAS scores recorded significant ( P<0.05) reductions in hot flushes, sweating and sleep disturbances in all groups after week 1 and highly significant ( P<0.0001) relief of all climacteric symptoms at week 52. Conclusion. Continuous combined HRT was associated with pronounced improvement of vasomotor symptoms and HRQoL in this population of early postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document